Navigation Links
Help Your Favorite Charity Win $1,000 from Cold-EEZE®!

DOYLESTOWN, Pa., Sept. 1, 2011 /PRNewswire/ -- ProPhase Labs (NASDAQ: PRPH), makers of Cold-EEZE®, announced today that they will be donating $1,000 to a well-deserving, locally nominated and voted upon charity every month for 18 months through their "Share Your Cause, Not Your Cold" contest, hosted exclusively on Facebook. The winning charity must be a registered, qualified and valid non-for-profit organization organized under the I.R.S. code 501(c)(3) and be located within the fifty (50) United States and the District of Columbia.

The contest will run from Thursday, September 1, 2011 at 9AM EDT through Sunday, April 1, 2012 at 11:59PM EDT. To nominate a local cause, all one must do is submit a "Cold-EEZE® Share Your Cause, Not Your Cold" Contest Nomination application at Once the nominations for that month have been gathered, a panel of judges selected by Cold-EEZE will select up to five finalists, to be voted on by fans across the nation. The fans will have approximately two weeks to vote and a winner will be announced at the end of every month. Each month a new cause will win $1,000 from Cold-EEZE®!

The winning organization will receive $1,000 and the person who nominated the cause will receive a Flip Camera to film their cause in action to help further awareness for the cause by obtaining footage that will be promoted on the Cold-EEZE® Website, and on the Cold-EEZE® Facebook Fan page, Each person is allowed one submission per month and is encouraged to spread the word to their social network and to encourage them to vote for their cause at!

"At Cold-EEZE®, we've always felt strongly about being involved in the community," says Ted Karkus, Chairman and CEO of ProPhase Labs. "Being involved in charitable work is just another way for Cold-EEZE® to help people feel better. We look forward to hearing all about the local causes that you care most about in your neighborhoods, contributing to them and sharing them with our entire community."

For the official rules and timeline for the "Share Your Cause, Not Your Cold" contest, please visit

About ProPhase Labs

ProPhase Labs (NASDAQ: PRPH) is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® cold remedy family of lozenges clinically

proven to significantly reduce the severity and duration of the common cold. Cold-EEZE® customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE® lozenges and fulfill other contract manufacturing opportunities.  ProPhase also owns 50% of Phusion Laboratories, LLC ("Phusion").  Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds.  Phusion will formulate and test products to exploit market opportunities within ProPhase's robust over-the-counter distribution channels.   For more information visit us at

Media Contact:  
Ilisa Wirgin/Jenny Miranda

SOURCE ProPhase Labs
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinerase® Introduces "Change Your Skin, Change Your Life" Charity Campaign
2. Amputees to Show Off Stand-Up Basketball Skills at Long Island, NY Charity Basketball Game
3. Orange County-Based Charity Teams Up With SunPower Corp. to Distribute Wheelchairs in the Philippines
4. Healthcare Scoring System Allows Hospitals To Increase Charity Care
5. OC-Based Charity Teams with International Relief Organization in Holiday Fundraising Drive
6. Hooters of Orange Park to Host Charity Car Wash Raising Money for Breast Cancer Research
7. UNICEF Partners With Causes on Facebook to Launch Charity Gift Feature
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Italian therapeutic drug monitoring ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of ... obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer ... 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified that on ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
(Date:11/25/2015)... MI (PRWEB) , ... November 25, 2015 , ... In ... Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy ... medical and surgical intensive care units (totaling 30 beds) from May 2014 through October ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood Treatment Center ... with eating disorders as a result of the $20,000 raised at the center’s ... Fox Run Golf Club in Eureka, will help individuals who otherwise might not ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
Breaking Medicine News(10 mins):